Figure 7.

Immunotherapy of Trop-2-expressing human cancer xenografts. Athymic nude mice were subcutaneously injected with the human SKOv3 ovarian, HCT116 U5.5 or Colo205 colon cancer cells. Injected mice were randomized (n = 16 per group) and treated with 30 mg/kg 2EF or 2G10 mAb administered weekly until sacrifice. The AR47A6.4.2 was used as a benchmark for anti-Trop-2 immunotherapy. Mice in the control groups received an irrelevant isotype-matched mAb. Red arrows: treatment was started at the time of injection of isolated tumor cells (time = 0) (SKOv3 ovarian cancer, upper panel) or when tumors reached an average volume of 100 mm³ (HCT116 U5.5, Colo205 colon cancers). Error bars: SEM. Significantly higher growth inhibition by 2EF versus control mAb was shown by the ANOVA test with Bonferroni post-hoc correction. *: p = 0.05; **: p = 0.01; ***: p = 0.0063, ****: p = 0.0038.